The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life in poor prognosis patients with locally advanced non-small cell lung cancer (LA-NSCLC) undergoing a phase II study of concurrent cetuximab and definitive thoracic radiotherapy followed by docetaxel and cetuximab.
Lora Thompson
No relevant relationships to disclose
Martine Extermann
Consultant or Advisory Role - GTx
Honoraria - Amgen; Sanofi
Thomas J. Dilling
No relevant relationships to disclose
Jongphil Kim
No relevant relationships to disclose
Binglin Yue
No relevant relationships to disclose
Craig William Stevens
No relevant relationships to disclose
Scott Antonia
No relevant relationships to disclose
Jhanelle Elaine Gray
No relevant relationships to disclose
Charles C. Williams
No relevant relationships to disclose
Eric B. Haura
No relevant relationships to disclose
Mary Colleen Pinder
No relevant relationships to disclose
Tawee Tanvetyanon
No relevant relationships to disclose
Alberto Chiappori
Honoraria - Lilly